sentence: Pre-clinical studies of the WEE1 inhibitor ( WEE1i ) adavosertib ( AZD1775 , MK 1775 ; AstraZeneca ) corroborate that WEE1i sensitizes P53-null tumors to radiation and cytotoxic chemotherapy by increasing mitotic catastrophe.25 Currently , adavosertib is the only WEE1i in clinical development .